The prediction to overcome the drug resistance in pancreatic cancers by proteomics and metaboromics.
Project/Area Number |
21591766
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | Tohoku University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
OOTSUKA Hideo 東北大学, 病院, 講師 (50451563)
OTSUKI Sumio 熊本大学, 生命科学研究部, 教授 (60323036)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 膵臓外科学 / 膵癌 / 抗癌剤 / プロテオミクス / メタボロミクス |
Research Abstract |
To clarify the resistant mechanism of gemcitabine(GEM), which is a standard agent for pancreatic cancer, a combination of targeted proteomic (LC-MS/MS)and metabolomic analyses were applied. The Attenuation of GEM phosphorylation by suppression of deoxycitidine kinase (dCK)was the most important mechanism for GEM resistance by using acquired resistant model and comparison of tissue expression profile and survival.
|
Report
(4 results)
Research Products
(48 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] 膵癌術前化学療法としてのGemcitabine+TS1療法(GS療法)の安全性・有効性の検証:NAC GS第II相臨床試験 第1次報告.(パネルディスカッション)2010
Author(s)
元井冬彦、乙供茂, 及川昌也, 岡田恭穂, 内山哲之, 井伊貴幸, 竹村真一, 岩指元, 島村弘宗, 赤田昌紀, 佐藤賢一, 片寄友, 江川新一, 下瀬川徹, 海野倫明
Organizer
第22回日本肝胆膵外科学会
Place of Presentation
仙台
Year and Date
2010-05-27
Related Report
-
-
-
-
-
-
-
-